Savara (NASDAQ:SVRA) Stock Sees Heavy Call Option Buying

Savara Inc. (NASDAQ:SVRA) saw unusually large options trading on Friday. Stock investors purchased 2,182 call options on the company. This represents an increase of 290% compared to the average daily volume of 560 call options.

Savara Stock Up 1.0%

Shares of SVRA stock traded up $0.04 on Friday, hitting $4.76. The stock had a trading volume of 564,646 shares, compared to its average volume of 1,803,927. Savara has a one year low of $4.13 and a one year high of $7.01. The business has a 50 day moving average price of $4.95 and a 200 day moving average price of $5.34. The company has a market cap of $1.05 billion, a PE ratio of -7.79 and a beta of 0.32. The company has a quick ratio of 10.13, a current ratio of 8.55 and a debt-to-equity ratio of 0.28.

Savara (NASDAQ:SVRA) last issued its earnings results on Monday, November 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.01. Research analysts anticipate that Savara will post -0.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

Several hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in Savara during the second quarter worth $76,966,000. Nantahala Capital Management LLC purchased a new position in shares of Savara in the 2nd quarter valued at $42,977,150. Spruce Street Capital LP bought a new position in shares of Savara in the 2nd quarter worth $21,267,868. Nan Fung Trinity HK Ltd. raised its position in shares of Savara by 1,088.3% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 1,842,350 shares of the company’s stock worth $9,507,000 after acquiring an additional 1,687,310 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Savara during the 2nd quarter worth $8,645,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

SVRA has been the subject of several recent analyst reports. JPMorgan Chase & Co. began coverage on shares of Savara in a research note on Wednesday, October 7th. They set an “overweight” rating and a $12.00 price objective for the company. Royal Bank Of Canada set a $10.00 target price on shares of Savara in a report on Wednesday, October 7th. HC Wainwright initiated coverage on shares of Savara in a research note on Thursday. They set a “buy” rating and a $10.00 price target for the company. Citigroup reiterated a “market outperform” rating on shares of Savara in a report on Wednesday, October 7th. Finally, Wall Street Zen downgraded shares of Savara from a “hold” rating to a “sell” rating in a report on Sunday, October 4th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Savara has an average rating of “Moderate Buy” and a consensus price target of $10.29.

About Savara

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.